Ascovent syrup

Indications

• Chronic obstructive pulmonary disease (COPD)
• Bronchitis
• Asthma
• Cystic fibrosis
• Respiratory infections with excessive mucus

Dosage

Children: Refer to the BNF for Children for specific dosing information.

Adults: Refer to the BNF for specific dosing information.

Mechanism of action

Acebrophylline acts by breaking down the structure of mucus, making it less viscous and easier to expectorate. Additionally, it may exert anti-inflammatory effects, decreasing the inflammatory response in the respiratory tract, although the specific pathways involved in these actions are not fully elucidated.

Pharmacodynamics

The pharmacodynamic effects of acebrophylline are primarily related to its action on mucus viscosity and inflammation. It promotes mucus clearance from the respiratory tract, improving pulmonary function and reducing symptoms associated with respiratory diseases. Its anti-inflammatory activity may further support respiratory health by mitigating underlying inflammatory processes.

Pharmacokinetics

The pharmacokinetics of acebrophylline include absorption, distribution, metabolism, and excretion characteristics. After oral administration, it is absorbed through the gastrointestinal tract. It is metabolised in the liver and has varying half-life depending on the individual’s metabolic rate. Excretion occurs primarily via the kidneys. However, specific values for these parameters are not provided.

Pregnancy

There are no adequate and well-controlled studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether acebrophylline is excreted in human milk. Caution should be exercised when administering to nursing women.

Storage

Store in a cool, dry place, away from light. Keep out of reach of children.